{"hands_on_practices": [{"introduction": "This first practice focuses on a foundational skill in clinical pharmacology: calculating a loading dose to rapidly achieve a therapeutic drug concentration. Using the case of phenytoin, we will address how to properly account for patient-specific variables such as obesity and low protein levels, which significantly impact the drug's initial distribution and effective concentration [@problem_id:4595987]. This exercise demonstrates the importance of moving beyond simple formulas to integrate patient data for a precise and safe initial dosing strategy.", "problem": "An adult male inpatient is undergoing Therapeutic Drug Monitoring (TDM) for phenytoin, an anticonvulsant with saturable metabolism but linear distribution for the purpose of loading dose calculation. The clinical goal is to determine a one-time intravenous (IV) phenytoin sodium loading dose that will raise the total phenytoin concentration to a specified therapeutic target using first principles of mass balance and pharmacokinetic definitions.\n\nPatient-specific data:\n- Total body weight (TBW): $108\\ \\mathrm{kg}$\n- Height: $172\\ \\mathrm{cm}$\n- Serum albumin: $2.4\\ \\mathrm{g/dL}$\n- Estimated glomerular filtration rate (eGFR): $90\\ \\mathrm{mL/min/1.73\\,m^2}$ (no advanced renal failure)\n- Measured total phenytoin concentration: $5.5\\ \\mathrm{mg/L}$\n- Desired target total phenytoin concentration: $15\\ \\mathrm{mg/L}$\n\nFoundational facts to use:\n- Ideal body weight (IBW) for males is given by the Devine formula: $\\mathrm{IBW_{male}} = 50\\ \\mathrm{kg} + 2.3\\ \\mathrm{kg/inch} \\times (\\text{inches over }5\\ \\text{feet})$. Use $1\\ \\mathrm{inch} = 2.54\\ \\mathrm{cm}$ and $5\\ \\text{feet} = 60\\ \\text{inches}$.\n- Adjusted body weight (AdjBW) in obesity is defined as $AdjBW = IBW + 0.4 \\cdot (TBW - IBW)$.\n- The apparent volume of distribution for phenytoin in adults can be taken as $0.65\\ \\mathrm{L/kg}$.\n- For hypoalbuminemia without advanced renal failure, correct the measured total phenytoin concentration using the Sheiner–Tozer relationship: $C_{\\text{corrected}} = \\dfrac{C_{\\text{measured}}}{0.2 \\cdot \\text{Albumin} + 0.1}$.\n- Intravenous phenytoin sodium is a salt form containing $0.92$ fraction of phenytoin base by mass; use this salt fraction in dose conversion.\n- Intravenous bioavailability is $F=1$.\n\nTask:\nUsing mass balance in the apparent distribution space and the definitions above, compute the single IV phenytoin sodium loading dose that will raise the total phenytoin concentration from the corrected current level to the target level.\n\nExpress the final dose in $\\mathrm{mg}$ of phenytoin sodium. Round your answer to three significant figures.", "solution": "The problem is to determine the intravenous (IV) phenytoin sodium loading dose required to increase a patient's total phenytoin concentration from its current measured level to a desired therapeutic target.\n\nFirst, a validation of the problem statement is performed.\n\n**Step 1: Extract Givens**\n- Total body weight (TBW): $108\\ \\mathrm{kg}$\n- Height: $172\\ \\mathrm{cm}$\n- Serum albumin (Albumin): $2.4\\ \\mathrm{g/dL}$\n- Estimated glomerular filtration rate (eGFR): $90\\ \\mathrm{mL/min/1.73\\,m^2}$ (no advanced renal failure)\n- Measured total phenytoin concentration ($C_{\\text{measured}}$): $5.5\\ \\mathrm{mg/L}$\n- Desired target total phenytoin concentration ($C_{\\text{target}}$): $15\\ \\mathrm{mg/L}$\n- Ideal body weight (IBW) for males: $\\mathrm{IBW_{male}} = 50\\ \\mathrm{kg} + 2.3\\ \\mathrm{kg/inch} \\times (\\text{inches over }5\\ \\text{feet})$\n- Conversion constant: $1\\ \\mathrm{inch} = 2.54\\ \\mathrm{cm}$\n- Conversion constant: $5\\ \\text{feet} = 60\\ \\text{inches}$\n- Adjusted body weight (AdjBW) in obesity: $AdjBW = IBW + 0.4 \\cdot (TBW - IBW)$\n- Apparent volume of distribution for phenytoin ($v_d$): $0.65\\ \\mathrm{L/kg}$\n- Sheiner–Tozer relationship for concentration correction: $C_{\\text{corrected}} = \\dfrac{C_{\\text{measured}}}{0.2 \\cdot \\text{Albumin} + 0.1}$\n- Salt fraction for phenytoin sodium ($S$): $0.92$\n- Intravenous bioavailability ($F$): $1$\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, as it uses standard pharmacokinetic principles and formulas (Devine, AdjBW, Sheiner-Tozer, loading dose calculation) that are well-established in clinical practice for therapeutic drug monitoring of phenytoin. The provided patient data are clinically plausible. The problem is well-posed, objective, and contains sufficient information to derive a unique, meaningful solution. No scientific flaws, contradictions, or ambiguities are present.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete, reasoned solution will be provided.\n\n**Solution Derivation**\n\nThe calculation proceeds in a logical sequence of steps.\n\n1.  **Determine the appropriate body weight for dosing.**\n    Phenytoin's volume of distribution is based on lean body mass. We must first calculate the patient's Ideal Body Weight (IBW) to assess for obesity and then determine the appropriate weight (IBW, TBW, or AdjBW) for the volume of distribution calculation.\n\n    -   Convert height from centimeters to inches:\n        $$ \\text{Height in inches} = \\frac{172\\ \\mathrm{cm}}{2.54\\ \\mathrm{cm/inch}} \\approx 67.7165\\ \\mathrm{inches} $$\n    -   Calculate inches over $5$ feet ($60$ inches):\n        $$ \\text{Inches over } 5\\ \\text{feet} = 67.7165 - 60 = 7.7165\\ \\mathrm{inches} $$\n    -   Calculate IBW using the Devine formula:\n        $$ \\mathrm{IBW} = 50\\ \\mathrm{kg} + 2.3\\ \\frac{\\mathrm{kg}}{\\mathrm{inch}} \\times 7.7165\\ \\mathrm{inches} \\approx 50 + 17.748\\ \\mathrm{kg} \\approx 67.75\\ \\mathrm{kg} $$\n    -   Assess for obesity. A common clinical definition for obesity is a TBW greater than $120\\%$ of IBW.\n        $$ 1.20 \\times \\mathrm{IBW} = 1.20 \\times 67.75\\ \\mathrm{kg} \\approx 81.30\\ \\mathrm{kg} $$\n        Since the patient's TBW ($108\\ \\mathrm{kg}$) is greater than $120\\%$ of their IBW ($81.30\\ \\mathrm{kg}$), the patient is considered obese. For obese patients, the Adjusted Body Weight (AdjBW) is typically used for phenytoin dose calculations.\n    -   Calculate AdjBW:\n        $$ \\mathrm{AdjBW} = \\mathrm{IBW} + 0.4 \\cdot (\\mathrm{TBW} - \\mathrm{IBW}) $$\n        $$ \\mathrm{AdjBW} = 67.75\\ \\mathrm{kg} + 0.4 \\cdot (108\\ \\mathrm{kg} - 67.75\\ \\mathrm{kg}) = 67.75\\ \\mathrm{kg} + 0.4 \\cdot (40.25\\ \\mathrm{kg}) \\approx 83.85\\ \\mathrm{kg} $$\n\n2.  **Calculate the patient's apparent volume of distribution ($V_d$).**\n    The total volume of distribution is the specific volume of distribution multiplied by the appropriate body weight (AdjBW).\n    $$ V_d = v_d \\times \\mathrm{AdjBW} = 0.65\\ \\frac{\\mathrm{L}}{\\mathrm{kg}} \\times 83.85\\ \\mathrm{kg} \\approx 54.50\\ \\mathrm{L} $$\n\n3.  **Correct the initial measured phenytoin concentration for hypoalbuminemia.**\n    Phenytoin is highly protein-bound to albumin. The patient's serum albumin is low ($2.4\\ \\mathrm{g/dL}$), which means a larger fraction of the drug is unbound and active. The Sheiner-Tozer equation corrects the measured total concentration to what it would be if albumin were normal ($4.4\\ \\mathrm{g/dL}$), providing a more clinically relevant baseline.\n    $$ C_{\\text{corrected}} = \\frac{C_{\\text{measured}}}{0.2 \\cdot \\text{Albumin} + 0.1} $$\n    $$ C_{\\text{corrected}} = \\frac{5.5\\ \\mathrm{mg/L}}{0.2 \\cdot (2.4) + 0.1} = \\frac{5.5}{0.48 + 0.1} = \\frac{5.5}{0.58}\\ \\mathrm{mg/L} \\approx 9.483\\ \\mathrm{mg/L} $$\n    This corrected concentration, $C_{\\text{corrected}}$, will be used as the initial concentration for the loading dose calculation.\n\n4.  **Calculate the required loading dose.**\n    A loading dose ($LD$) is calculated to fill the volume of distribution to achieve the desired concentration change. The fundamental mass balance relationship is:\n    $$ LD \\times S \\times F = \\Delta C \\times V_d $$\n    where $\\Delta C$ is the desired change in concentration ($C_{\\text{target}} - C_{\\text{corrected}}$).\n    Solving for the loading dose:\n    $$ LD = \\frac{(C_{\\text{target}} - C_{\\text{corrected}}) \\times V_d}{S \\times F} $$\n    -   The required change in concentration ($\\Delta C$) is:\n        $$ \\Delta C = 15\\ \\mathrm{mg/L} - 9.483\\ \\mathrm{mg/L} = 5.517\\ \\mathrm{mg/L} $$\n    -   Substitute all values into the loading dose equation:\n        $$ LD = \\frac{(5.517\\ \\mathrm{mg/L}) \\times (54.50\\ \\mathrm{L})}{0.92 \\times 1} $$\n    -   The mass of phenytoin base required is the numerator:\n        $$ \\text{Mass} = 5.517 \\times 54.50 \\approx 300.7\\ \\mathrm{mg} $$\n    -   The required dose of phenytoin sodium is:\n        $$ LD = \\frac{300.7\\ \\mathrm{mg}}{0.92} \\approx 326.8\\ \\mathrm{mg} $$\n\n5.  **Final Answer Rounding.**\n    The problem requires the final answer to be rounded to three significant figures.\n    $$ LD \\approx 327\\ \\mathrm{mg} $$\n\nThe single IV phenytoin sodium loading dose required is $327\\ \\mathrm{mg}$.", "answer": "$$\n\\boxed{327}\n$$", "id": "4595987"}, {"introduction": "Once a therapeutic concentration is established, the focus shifts to long-term maintenance. This exercise explores the unique challenge of adjusting maintenance doses for drugs with non-linear, saturable elimination, like phenytoin. Unlike drugs with linear kinetics, a small change in a phenytoin dose can lead to a disproportionately large change in its steady-state concentration, making precise adjustments crucial [@problem_id:4595991]. Here, we will apply the Michaelis-Menten model to calculate a safe dose increment, a core competency for managing anticonvulsants with complex elimination patterns.", "problem": "A patient with focal epilepsy is managed using extended-release oral phenytoin dosed once daily. Therapeutic Drug Monitoring (TDM) has yielded individualized parameters for saturable hepatic elimination described by Michaelis–Menten kinetics, with a maximum metabolic capacity $V_{\\max}$ and a Michaelis constant $K_{m}$. The dosage form provides approximately constant input over the $24$-hour dosing interval, oral bioavailability is constant and equal to $F$, albumin is normal, the patient is at steady state, and there are no enzyme inhibitors or inducers. The current daily oral dose is $200$ mg/day. Bayesian estimation from prior steady-state data has provided $V_{\\max} = 360$ mg/day and $K_{m} = 6.0$ mg/L for this patient. The clinical target total phenytoin concentration is $C_{\\text{target}} = 12$ mg/L. Assume the goal is to match the steady-state average input rate to the steady-state average elimination rate at $C_{\\text{target}}$ under Michaelis–Menten kinetics. The oral bioavailability is $F = 0.90$.\n\nStarting from steady-state mass balance and the definition of Michaelis–Menten elimination rate, derive the expression for the new required daily oral dose that would achieve $C_{\\text{target}}$ under the above assumptions. Then compute the safe dose increment, defined as the difference between the new required daily dose and the current daily dose. Round your answer to three significant figures and express the final answer in mg/day.", "solution": "The problem is deemed valid as it is scientifically grounded in the principles of clinical pharmacokinetics, specifically Michaelis-Menten elimination kinetics, and is well-posed with all necessary parameters provided for a unique solution. The given values for the Michaelis constant ($K_m$), maximum metabolic capacity ($V_{\\max}$), bioavailability ($F$), and target concentration ($C_{\\text{target}}$) are clinically plausible for phenytoin.\n\nThe fundamental principle for determining the required dose is the mass balance at steady state. At steady state, the average rate of drug administration must equal the average rate of drug elimination from the body.\n\nLet $D$ represent the daily oral dose in mg/day. The oral bioavailability, $F$, is the fraction of the administered dose that reaches the systemic circulation. The dosing interval, $\\tau$, is given as once daily, so $\\tau = 1$ day. The average rate of drug input into the systemic circulation, $R_{in}$, is therefore:\n$$R_{in} = \\frac{F \\times D}{\\tau} = \\frac{F \\times D}{1 \\text{ day}}$$\nSince $D$ is already expressed as a rate (mg/day), the input rate is simply $R_{in} = F \\times D$.\n\nThe elimination of phenytoin is described by saturable Michaelis-Menten kinetics. The rate of drug elimination, $R_{out}$, at a given plasma concentration $C$ is:\n$$R_{out} = \\frac{V_{\\max} \\times C}{K_m + C}$$\nwhere $V_{\\max}$ is the maximum rate of metabolism and $K_m$ is the Michaelis constant.\n\nThe problem asks to find the new daily oral dose, which we will denote as $D_{new}$, that achieves a target steady-state concentration, $C_{\\text{target}}$. The assumption of an extended-release formulation providing approximately constant input allows us to use the target concentration $C_{\\text{target}}$ as the average steady-state concentration in the elimination rate equation.\n\nAt steady state, we equate the rate of input for the new dose with the rate of elimination at the target concentration:\n$$R_{in} = R_{out}$$\n$$F \\times D_{new} = \\frac{V_{\\max} \\times C_{\\text{target}}}{K_m + C_{\\text{target}}}$$\n\nThe first part of the task is to derive the expression for the new required daily oral dose, $D_{new}$. We can achieve this by algebraically isolating $D_{new}$ in the equation above:\n$$D_{new} = \\frac{1}{F} \\left( \\frac{V_{\\max} \\times C_{\\text{target}}}{K_m + C_{\\text{target}}} \\right)$$\nThis is the general expression for the required daily dose.\n\nNow, we substitute the given numerical values into this expression to compute $D_{new}$:\n- Maximum metabolic capacity, $V_{\\max} = 360$ mg/day\n- Michaelis constant, $K_m = 6.0$ mg/L\n- Clinical target concentration, $C_{\\text{target}} = 12$ mg/L\n- Oral bioavailability, $F = 0.90$\n\n$$D_{new} = \\frac{1}{0.90} \\left( \\frac{360 \\text{ mg/day} \\times 12 \\text{ mg/L}}{6.0 \\text{ mg/L} + 12 \\text{ mg/L}} \\right)$$\n$$D_{new} = \\frac{1}{0.90} \\left( \\frac{4320}{18} \\right) \\text{ mg/day}$$\n$$D_{new} = \\frac{1}{0.90} \\left( 240 \\right) \\text{ mg/day}$$\n$$D_{new} = \\frac{240}{0.90} \\text{ mg/day} = \\frac{2400}{9} \\text{ mg/day} = \\frac{800}{3} \\text{ mg/day}$$\nNumerically, $D_{new} \\approx 266.666...$ mg/day.\n\nThe second part of the task is to compute the safe dose increment, defined as the difference between the new required daily dose ($D_{new}$) and the current daily dose ($D_{current}$). The current daily dose is given as $D_{current} = 200$ mg/day.\n\nThe dose increment, $\\Delta D$, is:\n$$\\Delta D = D_{new} - D_{current}$$\n$$\\Delta D = \\frac{800}{3} \\text{ mg/day} - 200 \\text{ mg/day}$$\nTo subtract, we express $200$ as a fraction with a denominator of $3$:\n$$200 = \\frac{200 \\times 3}{3} = \\frac{600}{3}$$\n$$\\Delta D = \\frac{800}{3} \\text{ mg/day} - \\frac{600}{3} \\text{ mg/day} = \\frac{200}{3} \\text{ mg/day}$$\n\nFinally, we compute the numerical value and round it to three significant figures as requested.\n$$\\Delta D = \\frac{200}{3} \\text{ mg/day} \\approx 66.666... \\text{ mg/day}$$\nRounding this value to three significant figures yields $66.7$ mg/day.", "answer": "$$\\boxed{66.7}$$", "id": "4595991"}, {"introduction": "Our final practice moves from calculation to complex clinical interpretation, highlighting that therapeutic drug monitoring is more than just comparing a number to a reference range. This advanced case study presents a patient exhibiting signs of phenytoin toxicity despite having a total drug concentration within the \"therapeutic\" window [@problem_id:4595981]. The challenge is to synthesize knowledge of protein binding, drug-drug interactions, and the influence of comorbidities to form a hypothesis that explains this discrepancy, reinforcing the principle that the unbound, or free, drug concentration is the ultimate driver of pharmacologic effect.", "problem": "A $62$-year-old man with focal epilepsy, chronic kidney disease stage $4$, and compensated cirrhosis presents with new-onset nystagmus, dysarthria, and truncal ataxia. His current antiseizure regimen is phenytoin extended-release $300$ $\\mathrm{mg}$ nightly and valproate $500$ $\\mathrm{mg}$ twice daily. Therapeutic Drug Monitoring (TDM) at clinic shows a trough total phenytoin concentration of $12$ $\\mathrm{mg/L}$ (laboratory therapeutic range $10$–$20$ $\\mathrm{mg/L}$) and a total valproate concentration of $75$ $\\mathrm{mg/L}$. Laboratory data: serum albumin $2.0$ $\\mathrm{g/dL}$, Blood Urea Nitrogen (BUN) $60$ $\\mathrm{mg/dL}$, serum creatinine $2.8$ $\\mathrm{mg/dL}$, total bilirubin $2.4$ $\\mathrm{mg/dL}$, international normalized ratio $1.3$. He denies recent dose changes, and sampling was obtained at steady state by history. Despite the total phenytoin result being within the commonly cited therapeutic range, his examination suggests toxicity.\n\nIn clinical pharmacology, only unbound drug is available to distribute to the biophase and produce pharmacologic effects. Albumin binding and competitive displacement by endogenous or exogenous ligands can alter the unbound fraction. Metabolic capacity, often mediated by cytochrome P450 (CYP) enzymes, and saturable elimination for certain anticonvulsants can further change the relationship between dose, total concentration, and free concentration at steady state.\n\nWhich of the following hypothesis-driven investigations most appropriately reconcile the observed toxicity with the measured total phenytoin concentration, and are supported by first-principles reasoning about protein binding, drug–drug interactions, and comorbidity? Select all that apply.\n\nA. Order an unbound (free) phenytoin concentration using equilibrium dialysis or ultrafiltration, and simultaneously assess serum albumin and Blood Urea Nitrogen (BUN), to test the hypothesis that hypoalbuminemia and uremic toxins increase the free fraction, yielding a toxic free level despite a “therapeutic” total level.\n\nB. Increase phenytoin by $50$ $\\mathrm{mg/day}$ because the total level is not above the upper limit of the laboratory’s therapeutic range, and toxicity is more likely due to disease progression than drug effect.\n\nC. Review concomitant valproate therapy and order both total and unbound valproate concentrations, together with repeat unbound phenytoin, to test the hypothesis that valproate displaces phenytoin from albumin and inhibits cytochrome P450 2C9 (CYP2C9), increasing free phenytoin and reducing clearance.\n\nD. Repeat a random total phenytoin level at a putative “peak” time rather than trough, because peak total concentrations better predict toxicity for long half-life drugs, and this will clarify whether the prior level missed a transient toxic peak.\n\nE. Obtain pharmacogenomic testing for cytochrome P450 2C9 and 2C19 polymorphisms and a comprehensive hepatic function panel, to evaluate decreased metabolic capacity (lower effective $V_{\\max}$) and saturable elimination, which could elevate unbound phenytoin at steady state even when total concentration appears “therapeutic.”", "solution": "This problem requires a multifactorial analysis of a complex clinical case. The core issue is the discrepancy between a \"therapeutic\" total phenytoin concentration and clear clinical signs of phenytoin toxicity. The solution lies in applying the free drug hypothesis and identifying all patient-specific factors that could increase the pharmacologically active unbound concentration.\n\n**Analysis of the Clinical Scenario:**\n- **Patient Presentation:** Nystagmus, dysarthria, and truncal ataxia are classic signs of phenytoin toxicity.\n- **Drug Level:** Total phenytoin is $12$ mg/L, within the typical $10-20$ mg/L range.\n- **Comorbidities:** The patient has several critical conditions that alter phenytoin pharmacokinetics:\n    1.  **Hypoalbuminemia:** Serum albumin is $2.0$ g/dL (normal range is typically $3.5-5.5$ g/dL). This reduces the number of available protein binding sites for phenytoin.\n    2.  **Chronic Kidney Disease (CKD):** Stage 4 CKD (indicated by high creatinine and BUN) leads to the accumulation of uremic toxins, which can competitively displace phenytoin from its binding sites on albumin.\n    3.  **Compensated Cirrhosis:** Liver disease can reduce the metabolic capacity (lower $V_{\\max}$) for phenytoin, which is hepatically cleared.\n- **Concomitant Medication:** The patient is on valproate, which is known to interact with phenytoin in two ways:\n    1.  **Protein Binding Displacement:** Valproate is also highly protein-bound and can displace phenytoin from albumin.\n    2.  **Metabolic Inhibition:** Valproate can inhibit CYP2C9, the primary enzyme that metabolizes phenytoin, thus reducing its clearance.\n\n**Evaluation of the Options:**\n\n*   **A. Correct.** This is the most direct and crucial first step. The patient has two strong reasons for an elevated free fraction ($f_u$): hypoalbuminemia and uremia. The free drug hypothesis predicts that the pharmacologically active unbound concentration is likely elevated and toxic, even if the total concentration is not. Ordering a free phenytoin level directly tests this primary hypothesis and is the standard of care in such situations.\n\n*   **B. Incorrect.** This action is clinically dangerous. It ignores the clear clinical signs of toxicity and the principle that the therapeutic range is a population guide, not an absolute rule for an individual. Increasing the dose of a drug with saturable, non-linear kinetics like phenytoin, especially in a patient already showing toxicity, could lead to a precipitous and life-threatening rise in concentration.\n\n*   **C. Correct.** This addresses a critical drug-drug interaction. Valproate is well-known to both displace phenytoin from albumin (increasing its free fraction) and inhibit its CYP2C9-mediated metabolism (decreasing its clearance). Both mechanisms would lead to a higher effective phenytoin concentration (higher free level and/or higher total level for a given dose). Investigating this interaction is a key part of understanding the complete pharmacokinetic picture.\n\n*   **D. Incorrect.** Phenytoin, especially an extended-release formulation, has a very long half-life, resulting in minimal peak-trough fluctuation at steady state. A trough concentration is the most reliable and standard sample for TDM. Attempting to measure a \"peak\" level is impractical and clinically uninformative; it would not address the fundamental issue of altered protein binding and clearance that is causing toxicity at a \"therapeutic\" total trough concentration.\n\n*   **E. Correct.** This option investigates both genetic and acquired factors that decrease phenytoin's metabolic capacity. A patient could be a genetic poor metabolizer of CYP2C9, which would inherently reduce their clearance. Furthermore, the patient's cirrhosis can reduce overall hepatic function, lowering the effective $V_{\\max}$ for phenytoin metabolism. Both factors would predispose the patient to accumulate the drug and reach toxicity at lower-than-usual doses. This is a valid and sophisticated part of a comprehensive workup to fully characterize the patient's individual pharmacokinetic profile.\n\n**Conclusion:**\nOptions A, C, and E represent a comprehensive and mechanistically sound approach to investigating the patient's toxicity. They correctly focus on the factors that influence the free concentration and clearance of phenytoin: altered protein binding (A), drug-drug interactions (C), and metabolic capacity (E). Options B and D are based on a misunderstanding of clinical toxicology and phenytoin pharmacokinetics.", "answer": "$$\\boxed{ACE}$$", "id": "4595981"}]}